paclitaxel has been researched along with Hypokalemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adessi, C; Albanell, J; Cejalvo, JM; Ceppi, M; Cervantes, A; Cortés, J; Dieras, V; Gonzalez, I; Hasmann, M; Jacob, W; James, I; Joly, F; Lassen, U; Levy, C; Lopez-Martin, J; Marmé, F; Martinez-Garcia, M; May, M; Meneses-Lorente, G; Michielin, F; Moisan, A; Park-Simon, TW; Racek, T; Schindler, C; Schneeweiss, A; Weisser, M; Welt, A | 1 |
| Fujitani, K; Furukawa, H; Imamura, H; Imano, M; Kimura, Y; Kurokawa, Y; Matsuoka, M; Shimokawa, T; Takiuchi, H; Tokunaga, Y; Tsujinaka, T; Yano, H | 1 |
2 trial(s) available for paclitaxel and Hypokalemia
| Article | Year |
|---|---|
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Hypokalemia; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptor, ErbB-3 | 2018 |
A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Fatigue; Female; Humans; Hypoalbuminemia; Hypokalemia; Hyponatremia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2013 |